A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Purpose
The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.
Condition
- Head and Neck Squamous Cell Carcinoma
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- ≥18 years of age - Willing and able to provide informed consent - Histologically- or cytologically-confirmed metastatic or unresectable, recurrent HNSCC unsuitable for local therapies - Intended for first line anti-PD1 or PDL1 monotherapy or combination therapy - Must submit tumor tissue sample representative of current disease per laboratory manual
Exclusion Criteria
- Non-squamous histologies (eg, nasopharynx or salivary gland) - Relapse or recurrence within 6 months of first line chemotherapy and / or chemoradiotherapy - Tumors that are PD-L1 negative (CPS <1) - Clinical evidence of an active second invasive malignancy within <2 years of enrollment with the exception of stable prostate cancer on watchful waiting, in situ cervical cancer, in situ breast carcinoma or localized non-melanoma skin cancers - Unable to comply with study procedures (i.e., not willing or able to have additional blood samples collected)
Study Design
- Phase
- Study Type
- Observational [Patient Registry]
- Observational Model
- Other
- Time Perspective
- Prospective
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Metastatic or unresectable recurrent HNSCC | Up to 500 participants (including primary tumor location of pharynx, larynx, oral cavity and oropharynx) with metastatic or unresectable recurrent HNSCC who are intended for first line immunotherapy or combination therapy. No intervention. |
Recruiting Locations
University of Kansas
Westwood, Kansas 66205
Westwood, Kansas 66205
More Details
- Status
- Recruiting
- Sponsor
- Tempus AI